Clinical trials: Hematopoietic Cell Transplant
Acute Myeloid Leukemia, Stem Cell Transplantation
GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia
Allogeneic stem cell transplantation is the only potentially curative therapy for patients with high-risk Acute Myeloid Leukaemia, but relapse is common and remains the leading cause of death.
- Conditions
- Acute Myeloid Leukemia, Stem Cell Transplantation, Stem Cell Transplantation, Hematopoietic, Cord Blood Stem Cell Transplantation
- Trial name
- GRACE (NCT07372885)
- Testing
- Cord blood transplantation + conditioning + granulocytes of variable days according to study design
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Manchester
Pediatric ALL, B Cell, Minimal Residual Disease
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
This is a single-arm, open-label, multi-center phase I study using blinatumomab for pediatric B-cell acute lymphoblastic leukemia patients with positive of minimal residual disease.
- Trial name
- NCT04604691
- Testing
- Blinatumomab for Injection
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Leukemia, Myelodysplastic Syndromes
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome
RATIONALE: Giving low doses of chemotherapy and antithymocyte globulin before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Trial name
- NCT00732316
- Testing
- nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Asan Medical Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00049504
- Testing
- cyclophosphamide, fludarabine phosphate, tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myelogenous Leukemia
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
The primary objective of this study is to evaluate the safety of gemtuzumab ozogamicin in relapsed CD33-positive AML patients who received HSCT. If the MTD dose is not reached, 9 mg/m2 will be the maximum tested dose.
- Trial name
- NCT00044733
- Testing
- Mylotarg (gemtuzumab ozogamicin) Injection
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Primary Objective Evaluate the efficacy of sitagliptin in reducing the incidence of grade II-IV acute Graft Versus-Host Disease (GvHD) by day +100 post-transplant in patients undergoing allogeneic hematopoietic stem cell…
- Trial name
- NCT02683525
- Testing
- Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Sherif S. Farag
Acute Myeloid Leukemia
Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial
In this trial the investigators will evaluate the outcomes of 4 pre-defined groups of individuals according to the therapeutic intervention.
- Trial name
- SIRA (NCT02867891)
- Volunteers
- 396 people
- Sponsor
- Robert Zeiser
Moxibustion, Hematopoietic Stem Cell Transplantation
Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two…
- Conditions
- Moxibustion, Hematopoietic Stem Cell Transplantation, Hemorrhagic Cystitis, Prevention
- Trial name
- NCT06198517
- Testing
- Moxibustion, Symptomatic treatment
- Where
- 4 sites in China
- Volunteers
- 303 people
- Sponsor
- Yi Zhang
Lymphoma, Lymphoma, B-Cell
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT.
- Conditions
- Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Hodgkin
- Trial name
- NCT05540340
- Testing
- Pharmacokinetics
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Graft Versus Host Disease, Hematopoietic/Lymphoid Cancer
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
This pilot clinical trial studies donor stem cell transplant followed by cyclophosphamide in treating patients with hematological diseases.
- Trial name
- NCT02248597
- Testing
- fludarabine phosphate, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma, Neoplasm, Plasma Cell
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT).
- Conditions
- Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms
- Trial name
- NCT04309084
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Celularity Incorporated
Relapse Leukemia, Refractory Acute Myeloid Leukemia
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML
The primary objective of this study was to evaluate the efficacy of MTBF conditioning regimen of salvageable allo-HSCT in patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Relapse Leukemia, Refractory Acute Myeloid Leukemia, Conditioning, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06385808
- Testing
- MTBF regimen
- Volunteers
- 37 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
This phase II trial is studying how well giving treosulfan together with fludarabine phosphate and total-body irradiation followed by donor stem cell transplant works in treating patients with high-risk acute myeloid leukemia…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00860574
- Testing
- treosulfan, fludarabine phosphate, total-body irradiation
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Fred Hutchinson Cancer Center
AML
A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)
The aim of this protocol is to investigate a novel form of immune therapy for patients with acute myelogenous leukemia (AML) who are in remission (CR) but who are at high risk for relapse.
- Trial name
- AMLCTL (NCT00808080)
- Testing
- AMLCTL
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Thomas A. Lane, MD
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure
- Trial name
- NCT03622788
- Testing
- Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Myelofibrosis, Chronic Myelomonocytic Leukemia
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse.
- Conditions
- Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT05233618
- Testing
- Tagraxofusp
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Karen Ballen, MD
T-cell Lymphoma, Graft Versus Host Disease
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma.
- Conditions
- T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell, Peripheral T Cell Lymphoma
- Trial name
- NCT07356245
- Testing
- Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Advanced MDS Without Identical Sibling Donor
Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome
Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS), especially for advanced MDS (blast >5%).
- Trial name
- NCT01793675
- Testing
- transplant with haploidentical donor
- Where
- 8 sites in China
- Volunteers
- 116 people
- Sponsor
- Peking University People's Hospital
Allogeneic Hematopoietic Cell Transplantation
TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders
The purpose of this study is to investigate the safety and efficacy of TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) for malignant and non-malignant disorders in children and adolescent/young adult…
- Trial name
- NCT04088760
- Testing
- TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Stem Cell Transplantation
Problem-Solving Skills Training for Parents of Children Undergoing Hematopoietic Stem Cell Transplantation: A Feasibility Study
The goal of this clinical trial is to test the feasibility and acceptability of the Bright IDEAS problem-solving skills training (PSST) intervention for parents of children undergoing hematopoietic stem cell transplantation…
- Trial name
- NCT07219524
- Testing
- Bright Ideas Problem-Solving Skills Training
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Children's Hospital Los Angeles
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.